Kazia Therapeutics Limited (KZIA)
| Market Cap | 151.86M +1,531.4% |
| Revenue (ttm) | 1.27M -24.2% |
| Net Income | -15.21M |
| EPS | -6.82 |
| Shares Out | 11.43M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 81,016 |
| Open | 13.35 |
| Previous Close | 13.52 |
| Day's Range | 13.09 - 13.77 |
| 52-Week Range | 4.86 - 17.40 |
| Beta | 2.14 |
| Analysts | Strong Buy |
| Price Target | 27.91 (+110.01%) |
| Earnings Date | Mar 30, 2026 |
About KZIA
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain met... [Read more]
Financial Performance
In fiscal year 2025, Kazia Therapeutics's revenue was 1.83 million, a decrease of -26.28% compared to the previous year's 2.48 million. Losses were -20.70 million, -22.69% less than in 2024.
Financial numbers in AUD Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for KZIA stock is "Strong Buy." The 12-month stock price target is $27.91, which is an increase of 110.01% from the latest price.
News
Kazia Therapeutics initiated with a Buy at Canaccord
Canaccord analyst John Newman initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $29 price target
Kazia Therapeutics initiated with a Buy at Canaccord on paxalisib potential
As previously reported, Canaccord initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $29 price target The firm sees lead asset paxalisib in triple negative breast cancer as…
Kazia Therapeutics Announces the Filing of Provisional Patent for Novel Strategy, Supported by Preclinical Data, to Prevent Metastatic Recurrence in Triple-Negative Breast Cancer
Clinically relevant perioperative studies demonstrate elimination of residual disease and prevention of metastatic spread, supported by complementary translational patient data Clinically relevant per...
Kazia Therapeutics initiated with a Buy at BTIG
BTIG analyst Kambiz Yazdi initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $34 price target Kazia is advancing paxalisib, which the firm calls “not simply a broader…
Kazia Therapeutics initiated with a Buy at Lake Street
Lake Street initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $32 price target The ongoing Phase 1b ABC-Pax study and its associated expanded access program have together…
Kazia Therapeutics appoints James Levine as CFO
Kazia Therapeutics (KZIA) appointed James Levine as CFO, effective June 1. Most recently, Levine served as CFO of Cardiff Oncology, a clinical-stage oncology company developing a PLK1 inhibitor therap...
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed to repro...
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
Planned Enrollment to Increase from 12 to 36 Patients Following Continued Encouraging Safety and Tolerability Data SYDNEY, May 26, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazi...
Kazia Therapeutics appoints Sudha Rao as Chief Scientific Officer
Kazia Therapeutics (KZIA) appointed Sudha Rao as Chief Scientific Officer, or CSO. Dr. Rao has more than 20 years of experience spanning pharmaceutical R&D, biotechnology, and early clinical developme...
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
SYDNEY, April 15, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), a clinical-stage oncology company developing differentiated therapies for cancers with high unmet need, today announced the ap...
Kazia Therapeutics initiated with a Buy at Laidlaw
Laidlaw initiated coverage of Kazia Therapeutics (KZIA) with a Buy rating and $25 price target Kazia is developing paxalisib, a novel dual PI3K/mTOR inhibitor, as a potential triple negative breast…
Kazia Therapeutics in-licenses drug development platform from QIMR Berghofer
Kazia Therapeutics (KZIA) announced the in-licensing of a SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The platform includes use of an AI-integrated epigenetic drug discov...
Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform
SYDNEY, Australia, April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer biology and overcome treatment re...
Kazia Therapeutics’ NDL2 shows anti-tumor efficacy in preclinical data
Kazia Therapeutics (KZIA) announced “compelling” preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively el...
Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an oncolo...
Kazia Therapeutics’ paxalisib shows clinical response in Phase 1b breast cancer
Kazia Therapeutics (KZIA) provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage, metastatic tri...
Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer
SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and che...
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to participate in meetings ...
Kazia Therapeutics trading resumes
16:00 EST Kazia Therapeutics (KZIA) trading resumes
Kazia Therapeutics trading halted, volatility trading pause
15:45 EST Kazia Therapeutics (KZIA) trading halted, volatility trading pause
Kazia Therapeutics regains Nasdaq compliance
Kazia Therapeutics (KZIA) announced that it has regained full compliance with all applicable listing standards of Nasdaq. On December 18, 2025, the company received written notification from Nasdaq co...
Kazia Therapeutics Regains Full Nasdaq Listing Compliance
Restoration of Nasdaq compliance follows $50 million institutional financing and reinforces balance-sheet strength SYDNEY , Dec. 22, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Co...
Kazia Therapeutics files to sell 10.7M American depositary shares for holders
16:49 EST Kazia Therapeutics (KZIA) files to sell 10.7M American depositary shares for holders
Kazia Therapeutics price target raised to $18 from $13 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Kazia Therapeutics (KZIA) to $18 from $13 and keeps a Buy rating on the shares. The company presented “encourating” results from its…
Kazia Therapeutics announces presentation from paxalisib studies
Kazia Therapeutics (KZIA) announced new data from two presentations at the 2025 San Antonio Breast Cancer Symposium, or SABCS, providing compelling mechanistic and early clinical evidence supporting t...